# Corrigendum: Genome-wide mapping of methylated adenine residues in pathogenic *Escherichia coli* using single-molecule real-time sequencing

Gang Fang, Diana Munera, David I Friedman, Anjali Mandlik, Michael C Chao, Onureena Banerjee, Zhixing Feng, Bojan Losic, Milind C Mahajan, Omar J Jabado, Gintaras Deikus, Tyson A Clark, Khai Luong, Iain A Murray, Brigid M Davis, Alona Keren-Paz, Andrew Chess, Richard J Roberts, Jonas Korlach, Steve W Turner, Vipin Kumar, Matthew K Waldor & Eric E Schadt *Nat. Biotechnol.* 30, 1232–1239 (2012); published online 8 November 2012; corrected after print 3 May 2013

In the version of this article initially published, on p. 1235, line 32, the wrong MTases were given for the motif GATC. Instead of "...GATC (for M.EcoGI and M.EcoGII)...," it should have read, "...GATC (for M.EcoGV and M.EcoGVII)...." The error has been corrected for the PDF and HTML versions of this article.

## Corrigendum: Industry pursues co-stimulatory receptor immunomodulators to treat cancer

#### Cormac Sheridan

Nat. Biotechnol. 31, 181-183 (2013); published online 7 March 2013; corrected after print 3 May 2013

In the version of this article initially published, the experimental drug nivolumab was incorrectly designated BMS-936588. The correct designation is BMS-936558. The error has been corrected in the HTML and PDF versions of the article.

### Erratum: Biotech's wellspring: the health of private biotech in 2012

#### Brady Huggett

Nat. Biotechnol. 31, 396–403 (2013); published online 8 May 2013; corrected after print 10 May 2013

In the version of this article initially published, in Table 1, the percentage of money placed into profitable biotechs in 2012 was incorrectly listed as 0.49. The correct percentage is 0.44. Also, in Table 3, the investor group Edmond de Rothschild Investment Partners was incorrectly listed as Rothschild. In Table 5, the "Other" category for investment in therapeutic modalities in 2011 was incorrectly listed as 812; the correct amount is 841. In Table 7, the total number of life sciences spinouts over the 2008–2012 period was incorrectly listed as 47,000. The correct number is 471. Finally, the call out for Figure 3 on p. 401, second column, was incorrectly labeled as Figure 2. The errors have been corrected in the HTML and PDF versions of the article.